GlassScriptPhysician profile
Sarina Pasricha
NPI 1871812529
$1,543.48
in general payments reported to CMS, 2019-2025
22 companies · $469 in 2025
The $469 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.34 · 2020: $47.69 · 2021: $168 · 2022: $200 · 2023: $302 · 2024: $276 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.98 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.77 | 2019-2025 | Gattex, Eohilia |
| Pfizer INC. | $111.85 | 2019-2025 | |
| Ardelyx, INC. | $85.45 | 2022-2025 | Ibsrela |
| Celgene Corporation | $69.21 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $63.66 | 2025 | Rezdiffra |
| Genzyme Corporation | $54.07 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.26 | 2023-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $43.31 | 2022-2025 | |
| Qol Medical, LLC | $42.55 | 2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $33.86 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $30.55 | 2022-2023 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $28.16 | 2024 | Blueboost, Dilation Balloons |
| Janssen Biotech, INC. | $26.90 | 2022-2024 | Tremfya |
| Daiichi Sankyo INC. | $24.34 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $24.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.92 | 2023 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $21.36 | 2023 | Andexxa |
| Lilly USA, LLC | $20.28 | 2025 | Omvoh |
| Shionogi INC | $17.08 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.64 | 2022 | |
| Merck Sharp & Dohme LLC | $16.07 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarina Pasricha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.